Andrew J. Roth

The FDA has approved the PARP inhibitor olaparib (Lynparza) for the treatment of women with BRCA-positive advanced ovarian cancer. The approval was based on results from a single-arm phase II study of patients with deleterious or suspected deleterious germline BRCA-mutated advanced cancers

The treatment of cancer is complex-an oncology team must monitor a patient's preexisting conditions, drug administration, side effects, and more. And, for patients with cancer, what may at first seem like a minor issue can quickly become an emergency.

Approximately one-third of cancer survivors in the US reported a financial problem or the need to modify work plans.

Radiotherapy is equally as effective in the palliation of dysphagia (difficulty swallowing) as chemoradiotherapy for patients with advanced esophageal cancer

Nobody Is Listening: Stories of Inflammatory Breast Cancer chronicles the accounts of women affected by inflammatory breast cancer, the most aggressive type of breast cancer.

Most deaths from breast cancer occur in women who have not been regularly screened and whose tumors are diagnosed at a median age 49 years, confirming the need for the greater use of annual mammography in younger women